Advancements in technology transfer to a Contract Development and Manufacturing Organization

In an exclusive interview, Roberto Formisano, Senior Manager of Process Transfer at AGC Biologics, discusses the challenges associated with technology transfer in the cell and gene therapy industry. He highlights the complexities involved in moving technology from development to GMP manufacturing, as well as from a customer to a contract development and manufacturing organization (CDMO).

During his conversation with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference on 19 March, Roberto emphasized the critical timelines that present the biggest challenges in technology transfer. He explained how balancing the number of batches that need to be manufactured is essential to ensuring sufficient and scientifically quality data within these timelines.

Roberto also shared his insights on the technology and manufacturing trends and priorities he foresees for the cell and gene therapy industry in 2024. He delved into the nuances of technology transfer and its implications for the industry during his interview with Peachey.

By Sophia Gonzalez

As a content writer at, I am dedicated to crafting engaging stories that captivate our readers. With a knack for turning complex topics into accessible and compelling narratives, I weave words together to inform and inspire. My passion lies in delivering accurate and thought-provoking content that keeps our audience informed and entertained. From breaking news stories to in-depth features, I strive to bring a fresh perspective to every piece I create. Join me on this journey of exploration and discovery through the power of words at

Leave a Reply